Literature DB >> 27525816

Engineering antibody therapeutics.

Mark L Chiu1, Gary L Gilliland2.   

Abstract

The successful introduction of antibody-based protein therapeutics into the arsenal of treatments for patients has within a few decades fostered intense innovation in the production and engineering of antibodies. Reviewed here are the methods currently used to produce antibodies along with how our knowledge of the structural and functional characterization of immunoglobulins has resulted in the engineering of antibodies to produce protein therapeutics with unique properties, both biological and biophysical, that are leading to novel therapeutic approaches. Antibody engineering includes the introduction of the antibody combining site (variable regions) into a host of architectures including bi and multi-specific formats that further impact the therapeutic properties leading to further advantages and successes in patient treatment.
Copyright © 2016 The Authors. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27525816     DOI: 10.1016/j.sbi.2016.07.012

Source DB:  PubMed          Journal:  Curr Opin Struct Biol        ISSN: 0959-440X            Impact factor:   6.809


  49 in total

Review 1.  Notch as a tumour suppressor.

Authors:  Craig S Nowell; Freddy Radtke
Journal:  Nat Rev Cancer       Date:  2017-02-03       Impact factor: 60.716

Review 2.  Passive Immunotherapies for Central Nervous System Disorders: Current Delivery Challenges and New Approaches.

Authors:  Niyanta N Kumar; Michelle E Pizzo; Geetika Nehra; Brynna Wilken-Resman; Sam Boroumand; Robert G Thorne
Journal:  Bioconjug Chem       Date:  2018-10-24       Impact factor: 4.774

Review 3.  Impact of the Protein Data Bank on antineoplastic approvals.

Authors:  John D Westbrook; Rose Soskind; Brian P Hudson; Stephen K Burley
Journal:  Drug Discov Today       Date:  2020-02-14       Impact factor: 7.851

4.  PRESCIENT: platform for the rapid evaluation of antibody success using integrated microfluidics enabled technology.

Authors:  Jose A Wippold; Han Wang; Joseph Tingling; Julian L Leibowitz; Paul de Figueiredo; Arum Han
Journal:  Lab Chip       Date:  2020-03-20       Impact factor: 6.799

Review 5.  Preclinical optimization of antibody-based radiopharmaceuticals for cancer imaging and radionuclide therapy-Model, vector, and radionuclide selection.

Authors:  Lukas M Carter; Sophie Poty; Sai Kiran Sharma; Jason S Lewis
Journal:  J Labelled Comp Radiopharm       Date:  2018-03-30       Impact factor: 1.921

Review 6.  Overcoming Tumor-Induced Immune Suppression: From Relieving Inhibition to Providing Costimulation with T Cell Agonists.

Authors:  Dana A Emerson; William L Redmond
Journal:  BioDrugs       Date:  2018-06       Impact factor: 5.807

7.  Epitope-specific affinity maturation improved stability of potent protease inhibitory antibodies.

Authors:  Tyler Lopez; Chen Chuan; Aaron Ramirez; Kuan-Hui E Chen; Mary Y Lorenson; Chris Benitez; Zahid Mustafa; Henry Pham; Ramon Sanchez; Ameae M Walker; Xin Ge
Journal:  Biotechnol Bioeng       Date:  2018-09-15       Impact factor: 4.530

8.  Antitumor activity of an engineered decoy receptor targeting CLCF1-CNTFR signaling in lung adenocarcinoma.

Authors:  Jun W Kim; Cesar P Marquez; Kaja Kostyrko; Amanda L Koehne; Kieren Marini; David R Simpson; Alex G Lee; Stanley G Leung; Leanne C Sayles; Joseph Shrager; Irene Ferrer; Luis Paz-Ares; Melanie Hayden Gephart; Silvestre Vicent; Jennifer R Cochran; E Alejandro Sweet-Cordero
Journal:  Nat Med       Date:  2019-11-07       Impact factor: 53.440

Review 9.  Camelid Single-Domain Antibodies for the Development of Potent Diagnosis Platforms.

Authors:  Nairo Brilhante-da-Silva; Rosa Maria de Oliveira Sousa; Andrelisse Arruda; Eliza Lima Dos Santos; Anna Carolina Machado Marinho; Rodrigo Guerino Stabeli; Carla Freire Celedonio Fernandes; Soraya Dos Santos Pereira
Journal:  Mol Diagn Ther       Date:  2021-06-19       Impact factor: 4.074

Review 10.  Stepping forward in antibody-drug conjugate development.

Authors:  Yiming Jin; Megan A Schladetsch; Xueting Huang; Marcy J Balunas; Andrew J Wiemer
Journal:  Pharmacol Ther       Date:  2021-06-24       Impact factor: 12.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.